Alma Biotherapeutics

is pursuing a curative approach to the treatment of immune diseases by developing drugs based on the way the immune system distinguishes between healthy cells and the ‘other’ cells the immune system is designed to eliminate.

OUR MISSION

Alma Biotherapeutics is advancing a new approach to the treatment of autoimmune diseases. The approach attempts to restore balance to the immune system.

Irun Cohen, cofounder of Alma, conducted decades of research geared to increasing the understanding of autoimmune diseases. Those discoveries laid a foundation for developing therapies to curtail damaging autoimmunity without suppressing the immune system.

The team at Alma Biotherapeutic is striving to improve the current treatment of inflammatory bowel disease or IBD and other autoimmune diseases. Activating the immune system to better regulate itself would mark an improvement over the way autoimmune diseases are currently treated.

Alma Biotherapeutics is advancing a therapy to treat IBD. The therapy is designed to selectively halt the immune system’s attack on the intestine (Crohn’s Disease) by using its own signals. These signals are called Heat Shock Proteins (HSP).

Healthcare Facts

M

Autoimmune Diseases are among the leading public health problems of the 21st century. There are more than 100 Million patients worldwide, including over 20 Million in Europe.

There are than 90 different types of autoimmune diseases. Notably juvenile diabetes, rheumatoid arthritis, IBD, multiple sclerosis, and psoriasis are among the diseases caused when the immune system turns on the body’s own tissues.

%

The incidence of autoimmune diseases is on the rise and approaching epidemic proportions. According to the French Inflammatory Bowel Disease or IBD Association the incidence of IBD has risen by 60% over an 8 year period.

B€

Revenues from therapies to treat autoimmune diseases currently exceed €60 billion annually

Meet the team

The founders and team behind Alma Biotherapeutics are motivated by the mission to improve the way autoimmune diseases are treated.

Dr. Binah Baum Dr. Binah Baum CEO and co Founder

Dr. Binah Baum

CEO and co Founder

Dr. Binah Baum

A seasoned biopharmaceutical executive and serial entrepreneur, Dr, Baum has participated in the founding of over 30 start ups located in Europe, the US and Israel. To-date, six have had successful exits. Dr. Baum teamed up with Dr. Cohen’s in founding Alma Biotherapeutics in order to apply new knowledge of the mechanisms underlying autoimmune disease to the development of therapeutic interventions for these chronic conditions.

X
Prof. Irun Cohen Prof. Irun Cohen Inventor, Chief Scientific Advisor and co Founder

Prof. Irun Cohen

Inventor, Chief Scientific Advisor and co Founder

Prof. Irun Cohen

Decades of research conducted by Dr. Cohen are the foundation for Alma’s Biotherapeutics drug discovery and development platform. Dr. Cohen is a world leading research immunologist who has received the Robert Koch Prize  and the AESKU Prize for his Life Contribution to Autoimmunity Research. Dr. Cohen remains a Professor Emeritus of Immunology, Weizmann Institute of Science.

X
Dr. Denis Ravel Dr. Denis Ravel Director of Preclinical Development and Regulatory Affairs

Dr. Denis Ravel

Director of Preclinical Development and Regulatory Affairs

Dr. Denis Ravel

Dr. Ravel brings 30 years’ experience as executive who has ushered drugs from concept to to the clinic for bio-pharmaceutical companies including Servier, Genset/MerckSerono, and Diatos.

X

“Immunity is a balancing act. Our approach attempts to tilt the balance away from the harmful inflammation associated with autoimmune diseases and toward healing.”  World Leading Research Immunologist, Irun Cohen, Professor Emeritus of Immunology

Our Technology

Social Media

Stay up-to-date with our latest company news, and life blogsentries via your favourite social network services.

Get in touch

 


 

LEGAL NOTICE